FY2025 EPS Estimates for Hologic Boosted by Leerink Partnrs

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for Hologic in a research note issued on Wednesday, December 11th. Leerink Partnrs analyst P. Souda now forecasts that the medical equipment provider will post earnings per share of $4.31 for the year, up from their prior forecast of $4.27. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Hologic’s Q4 2025 earnings at $1.14 EPS, Q1 2026 earnings at $1.12 EPS, Q2 2026 earnings at $1.16 EPS, Q3 2026 earnings at $1.20 EPS, Q4 2026 earnings at $1.21 EPS and FY2026 earnings at $4.69 EPS.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. The business’s revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the business earned $0.89 EPS.

Several other brokerages also recently weighed in on HOLX. Raymond James increased their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Leerink Partners reduced their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and lowered their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, December 10th. Finally, BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $89.50.

Hologic Stock Down 0.2 %

Shares of NASDAQ HOLX opened at $72.26 on Monday. Hologic has a 1 year low of $70.24 and a 1 year high of $84.67. The firm has a 50-day simple moving average of $79.01 and a two-hundred day simple moving average of $78.62. The company has a market cap of $16.40 billion, a P/E ratio of 21.70, a PEG ratio of 2.38 and a beta of 0.96. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Institutional Investors Weigh In On Hologic

A number of hedge funds and other institutional investors have recently bought and sold shares of HOLX. Andra AP fonden increased its position in shares of Hologic by 224.5% during the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock worth $7,083,000 after purchasing an additional 66,000 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Hologic by 17.9% during the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock worth $312,000 after acquiring an additional 582 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Hologic by 2.9% in the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after purchasing an additional 800 shares during the last quarter. Quest Partners LLC grew its position in Hologic by 56.1% during the 2nd quarter. Quest Partners LLC now owns 41,492 shares of the medical equipment provider’s stock worth $3,081,000 after purchasing an additional 14,914 shares during the last quarter. Finally, Versor Investments LP purchased a new position in shares of Hologic in the third quarter worth $1,677,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Activity at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.75% of the stock is currently owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.